Fig. 3From: Evaluation of dosing strategy for pembrolizumab for oncology indicationsConsistency of observed concentrations in patients with predictions based on population PK model: Pembrolizumab concentration-time profiles during the first dose (left panels) and at steady state (right panels) of repeated dosing at 2 mg/kg Q3W (top panels) and 200 mg Q3W (bottom panels). Solid markers represent observed pembrolizumab serum concentrations. Solid line represents median predicted concentration time profile, based on the population PK model. Shaded areas represent 90% prediction interval for the predictionBack to article page